Robert Huizinga
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Robert Huizinga
Aurinia Pharmaceuticals Inc. reported in an 8-K filed October 21, 2022 that Robert Huizinga was terminated as Executive Vice President, Research, effective October 31, 2022.
“On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Aurinia Pharmaceuticals Inc. (AUPH)
Proxy statement
Start not stated–2022-10-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.